Historical Valuation
Takeda Pharmaceutical Co Ltd (TAK) is now in the Fair zone, suggesting that its current forward PE ratio of 31.86 is considered Fairly compared with the five-year average of 27.13. The fair price of Takeda Pharmaceutical Co Ltd (TAK) is between 8.54 to 19.11 according to relative valuation methord.
Relative Value
Fair Zone
8.54-19.11
Current Price：16.31
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Takeda Pharmaceutical Co Ltd (TAK) has a current Price-to-Book (P/B) ratio of 1.08. Compared to its 3-year average P/B ratio of 0.91 , the current P/B ratio is approximately 19.57% higher. Relative to its 5-year average P/B ratio of 0.96, the current P/B ratio is about 13.04% higher. Takeda Pharmaceutical Co Ltd (TAK) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 11.70%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 13.37% , the current FCF yield is about -100.00% lower.
P/B
Median3y
0.91
Median5y
0.96
FCF Yield
Median3y
11.70
Median5y
13.37
Competitors Valuation Multiple
AI Analysis for TAK
The average P/S ratio for TAK competitors is 7.35, providing a benchmark for relative valuation. Takeda Pharmaceutical Co Ltd Corp (TAK.N) exhibits a P/S ratio of , which is -100% above the industry average. Given its robust revenue growth of -5.38%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for TAK
1Y
3Y
5Y
Market capitalization of TAK increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TAK in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is TAK currently overvalued or undervalued?
Takeda Pharmaceutical Co Ltd (TAK) is now in the Fair zone, suggesting that its current forward PE ratio of 31.86 is considered Fairly compared with the five-year average of 27.13. The fair price of Takeda Pharmaceutical Co Ltd (TAK) is between 8.54 to 19.11 according to relative valuation methord.
What is Takeda Pharmaceutical Co Ltd (TAK) fair value?
TAK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Takeda Pharmaceutical Co Ltd (TAK) is between 8.54 to 19.11 according to relative valuation methord.
How does TAK's valuation metrics compare to the industry average?
The average P/S ratio for TAK's competitors is 7.35, providing a benchmark for relative valuation. Takeda Pharmaceutical Co Ltd Corp (TAK) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -5.38%, this premium appears unsustainable.
What is the current P/B ratio for Takeda Pharmaceutical Co Ltd (TAK) as of Jan 10 2026?
As of Jan 10 2026, Takeda Pharmaceutical Co Ltd (TAK) has a P/B ratio of 1.08. This indicates that the market values TAK at 1.08 times its book value.
What is the current FCF Yield for Takeda Pharmaceutical Co Ltd (TAK) as of Jan 10 2026?
As of Jan 10 2026, Takeda Pharmaceutical Co Ltd (TAK) has a FCF Yield of 0.00%. This means that for every dollar of Takeda Pharmaceutical Co Ltd’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for Takeda Pharmaceutical Co Ltd (TAK) as of Jan 10 2026?
As of Jan 10 2026, Takeda Pharmaceutical Co Ltd (TAK) has a Forward P/E ratio of 31.86. This means the market is willing to pay $31.86 for every dollar of Takeda Pharmaceutical Co Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Takeda Pharmaceutical Co Ltd (TAK) as of Jan 10 2026?
As of Jan 10 2026, Takeda Pharmaceutical Co Ltd (TAK) has a Forward P/S ratio of 0.00. This means the market is valuing TAK at $0.00 for every dollar of expected revenue over the next 12 months.